Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Essential Therapeutics (ETRX) formerly Microcide (MCDE -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (357)	6/13/2001 1:43:01 PM
From: nigel bates	Read Replies (1) \| Respond to of 415

Parking... paratekpharm.com remedyne.com Remedyne's founding scientists have discovered that an enzyme in Salmonella spp., DNA Adenine Methylase (DAM), acts as a global regulator (master switch) to regulate at least 37 genes that are specifically activated when bacteria enter a host and begin to cause disease. When the dam gene is disabled or overactive (DAM mutants), the ability of the bacteria to cause disease is profoundly attenuated. Further research has shown that the immune systems of lab animals vaccinated with DAM mutants become strongly primed to defend against subsequent infection by pathogenic bacterial strains. These discoveries form the basis for our three types of therapeutic products: vaccines for Salmonella and those bacteria with a dam gene; a carrier vaccine platform based upon Salmonella for pathogens without a dam gene, including bacteria, viruses, parasites, and fungi; and antibiotics against DAM containing pathogens.